secwatch.observer — SEC 8-K summary
======================================

Issuer:     Baudax Bio, Inc. (—)
CIK:        0001780097
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277889
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Baudax Bio receives Nasdaq delisting notice; suspension Nov 16
--------------------------------------------------------------

- Nasdaq Panel determined to delist BXRX common stock for failure to meet initial listing requirements by Nov 13, 2023.
- Trading suspension on Nasdaq Capital Market effective at opening on November 16, 2023.
- Company has 15 days to request a review by the Nasdaq Listing and Hearing Review Council.
- If no timely request, Form 25-NSE will be filed removing securities from Nasdaq registration.
- Stock may become eligible for OTC trading, but no assurance is given.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523277889/0001193125-23-277889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523277889/d850440d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer